ID Source | ID |
---|---|
PubMed CID | 71353 |
CHEMBL ID | 2110900 |
CHEBI ID | 135962 |
SCHEMBL ID | 34479 |
MeSH ID | M0215302 |
Synonym |
---|
n,n-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]-benzenemethanamine |
AB01274725-01 |
ly-210448 |
dapoxetine , |
ly 210448 |
dapoxetinum [inn-latin] |
benzenemethanamine, n,n-dimethyl-alpha-(2-(1-naphthalenyloxy)ethyl)-, (+)- |
dapoxetina [inn-spanish] |
dapoxetine [inn] |
ly210448 |
CHEBI:135962 |
(1s)-n,n-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine |
A804264 |
(s-(+)-n,n-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine hydrochloride;d-dapoxetine hydrochloride |
119356-77-3 |
dapoxetin |
(s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine |
dapoxetinum |
dapoxetina |
unii-gb2433a4m3 |
gb2433a4m3 , |
NCGC00253658-02 |
AKOS015895183 |
gtpl7901 |
DB04884 |
SCHEMBL34479 |
cas-119356-77-3 |
NCGC00253658-01 |
dtxsid0057627 , |
tox21_113784 |
dtxcid1031416 |
kutub |
dapoxetine [mart.] |
dapoxetine [mi] |
dapoxetine [who-dd] |
(+)-(s)-n,n-dimethyl-.alpha.-(2-(1-naphthyloxy)ethyl)benzylamine |
benzenemethanamine, n,n-dimethyl-.alpha.-(2-(1-naphthalenyloxy)ethyl)- |
USRHYDPUVLEVMC-FQEVSTJZSA-N |
CHEMBL2110900 |
AC-22603 |
AB01274725_02 |
AS-72866 |
dimethyl[(1s)-3-(naphthalen-1-yloxy)-1-phenylpropyl]amine |
dapoxetine (free base) |
Q424965 |
EX-A4045 |
s-(+)-n,n-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine |
benzenemethanamine, n,n-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]-, (alphas)- |
HY-B0304 |
Dapoxetine (DAP) is a serotonin-norepinephrine reuptake inhibitor, and Tadalafil (TAD) is an phosphodiesterase type-5 inhibitor. It is the first drug approved for the on-demand treatment of premature ejaculation (PE)
Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs) It has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies.
Dapoxetine treatment significantly prolonged IELT and improved PEP measures and was generally well tolerated in men with PE in the Asia-Pacific region.
Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events. Preclinical safety pharmacology studies did not suggest an adverse electrophysiologic or hemodynamic effect with concentrations of dapoxETine up to 2-fold greater than recommended doses.
Dapoxetine is being developed as a treatment for premature ejaculation and has demonstrated rapid absorption and elimination in previous pharmacokinetic studies. The aim of study is to develop a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to investigate the drug interaction.
Excerpt | Reference | Relevance |
---|---|---|
"Potential pharmacokinetic interactions between dapoxetine, a serotonin transporter inhibitor developed for the treatment of premature ejaculation (PE), and the phosphodiesterase-5 inhibitors tadalafil and sildenafil, agents used in the treatment of erectile dysfunction (ED), were investigated in an open-label, randomized, crossover study (n=24 men) comparing dapoxetine 60 mg, dapoxetine 60 mg+tadalafil 20 mg, and dapoxetine 60 mg+sildenafil 100 mg." | ( Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Desai, D; Dresser, MJ; Gidwani, S; Modi, NB; Seftel, AD, ) | 1.83 |
"To describe the relationship between the pharmacokinetic and pharmacodynamic properties of dapoxetine, a drug specifically developed for treating premature ejaculation (PE)." | ( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Andersson, KE; Mulhall, JP; Wyllie, MG, 2006) | 0.81 |
" The clinical characteristics were then compared with the pharmacokinetic profile, determined from measured plasma drug concentrations." | ( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Andersson, KE; Mulhall, JP; Wyllie, MG, 2006) | 0.59 |
"Pharmacodynamic and pharmacokinetic measurements confirm that 'on demand' dapoxetine has a rapid onset of action and is rapidly cleared after sexual intercourse." | ( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Andersson, KE; Mulhall, JP; Wyllie, MG, 2006) | 0.82 |
" Its physicochemical and pharmacokinetic properties and its clinical efficacy make dapoxetine suitable for on-demand treatment of PE." | ( Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation. Andersson, KE; Mulhall, JP; Wyllie, MG, 2006) | 0.81 |
"Dapoxetine is being developed as a treatment for premature ejaculation and has demonstrated rapid absorption and elimination in previous pharmacokinetic studies." | ( Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. Dresser, MJ; Gidwani, S; Guo, C; Kang, D; Modi, NB; Mulhall, JP; Staehr, P, 2006) | 2.1 |
" Dapoxetine was eliminated in a biphasic manner with an apparent mean terminal half-life of 14 to 17 hours." | ( Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men. Aquilina, JW; Hsiao, HL; Mudumbi, R; Sharma, O; Thyssen, A; Tianmei, S; Vandebosch, A; Wang, SS, 2010) | 1.59 |
" The aim of the study reported here was to investigate the pharmacokinetic drug interaction between udenafil and dapoxetine in healthy male subjects." | ( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015) | 0.88 |
" Pharmacokinetic parameters were obtained by non-compartmental analysis." | ( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015) | 0.67 |
"Udenafil was found to have no clinically significant pharmacokinetic interactions with dapoxetine." | ( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015) | 0.89 |
"The aim of study is to develop a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method to investigate the pharmacokinetic interaction of Epimedium extract on the dapoxetine in rats." | ( Herb-drug interaction of Epimedium extract on the pharmacokinetic of dapoxetine in rats. Chiu, AW; Ho, JK; Hsueh, TY; Lin, CH; Lin, LC; Tsai, TH, 2016) | 0.86 |
" Plasma concentration of dapoxetine was determined by high-performance liquid chromatography-tandem mass spectrometry, and the pharmacokinetic parameters were calculated using noncompartmental analysis." | ( Pharmacokinetics and Safety of Dapoxetine Hydrochloride in Healthy Chinese Men: Impact of Dose and High-Fat Meal. Ju, G; Li, Z; Liu, J; Qiu, W; Yan, K, 2021) | 1.21 |
To evaluate the efficacy and safety of tamsulosin combined with dapoxetine in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) that is complicated by premature ejaculation.
Excerpt | Reference | Relevance |
---|---|---|
"To evaluate the overall treatment benefits of premature ejaculation desensitisation therapy combined with 30 mg dapoxetine hydrochloride treatment on patients with primary premature ejaculation (PPE)." | ( Effect of premature ejaculation desensitisation therapy combined with dapoxetine hydrochloride on the treatment of primary premature ejaculation. Fu, M; Hu, Y; Peng, X, 2019) | 0.96 |
"To evaluate the efficacy and safety of tamsulosin combined with dapoxetine in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) that is complicated by premature ejaculation (PE), a total of 251 CP/CPPS patients with PE were recruited from nine hospitals across China and were randomly divided into two groups: one received tamsulosin as a control, and the other received a combination therapy of tamsulosin and dapoxetine." | ( Beneficial effect of tamsulosin combined with dapoxetine in management of type III prostatitis with premature ejaculation. Ji, Z; Li, Z; Liang, C; Song, W; Tian, R; Wang, Z; Xia, S; Zhang, L; Zhao, J; Zhao, L, 2019) | 1.01 |
"To evaluate the safety and efficacy of Chinese medicine, Qiaoshao formula combined with dapoxetine was used for the treatment of premature ejaculation in a real-life setting." | ( Safety and efficacy of traditional Chinese medicine, Qiaoshao formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men. Bin, B; Cai, J; Colonnello, E; Gao, Q; Geng, Q; Guo, B; Guo, J; Han, Q; Jannini, EA; Wang, F; Xuan, Z; Yan, B; Zhang, C; Zhang, J; Zhang, R; Zhou, Q, 2021) | 1.07 |
"To observe the clinical effect of priligy (dapoxetine hydrochloride) combined with behavioral therapy and psychological counseling in the treatment of primary premature ejaculation (PPE)." | ( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation]. Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020) | 0.82 |
"A total of 202 PPE patients diagnosed from 2017 to 2018 were randomized into a control (n = 100) and an experimental group (n = 102), the former treated with oral priligy at 30 mg 1-3 hours before anticipated sexual activity, and the latter by the same medication combined with 30-minute behavioral therapy and psychological counseling once a month for two times." | ( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation]. Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020) | 0.56 |
"Priligy combined with behavioral therapy and psychological counseling is more effective than priligy alone in improving the sexual function of PPE patients, raise their interest in sexual life and increase the intimacy between the partners, and can even achieve clinical cure in some patients." | ( [Priligy combined with behavioral therapy and psychological counseling for primary premature ejaculation]. Cai, DY; Guo, KM; Li, FB; Wang, HL; Wu, J; Xu, SQ; Yang, YP, 2020) | 0.56 |
Dapoxetine (DPX), a recently approved drug for the treatment of PE, suffers from low bioavailability with large variability that ranges from 15-76% (mean 42%) after oral administration.
The presented study is using previously analyzed pharmaceutical mixtures of Dapoxetine Hydrochloride (DAP) and Tadalafil (TAD) as a case study. Phase I clinical pharmacology studies demonstrated that dap Oxetine did not prolong the QT/QTc interval and had neither clinically sign up. In the 3 ethnic groups, dapOxetine was rapidly absorbed following oral administration.
Excerpt | Relevance | Reference |
---|---|---|
" Most tissues had returned to background radioactive levels 72 h after dosing but persistent concentrations of radiocarbon were present in the preputial gland and liver one week after the single dose of 14C-dapoxetine." | ( Disposition of 14C-dapoxetine in rats: complementary experiments with whole-body autoradiographic and tissue dissection techniques. Bernstein, JR; Franklin, RB; Manzione, BM; Pohland, RC, 1994) | 0.8 |
" The process of ejaculation is under central control, and serotonin (5-HT) is a key mediator; therefore, SSRIs and tricyclic antidepressants, including paroxetine, sertraline and clomipramine, are commonly used with chronic daily dosing in the treatment of PE." | ( Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation. Hellstrom, WJ; Patel, K, 2009) | 0.35 |
" In the 3 ethnic groups, dapoxetine was rapidly absorbed following oral administration, with peak plasma concentrations evident approximately 1 hour after dosing, independent of dose, dosing frequency (single or multiple dosing), or ethnicity." | ( Pharmacokinetics of dapoxetine hydrochloride in healthy Chinese, Japanese, and Caucasian men. Aquilina, JW; Hsiao, HL; Mudumbi, R; Sharma, O; Thyssen, A; Tianmei, S; Vandebosch, A; Wang, SS, 2010) | 0.99 |
" Phase I clinical pharmacology studies demonstrated that dapoxetine did not prolong the QT/QTc interval and had neither clinically significant electrocardiographic effects nor evidence of delayed repolarization or conduction effects, with dosing up to 4-fold greater than the maximum recommended dosage." | ( Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Aquilina, JW; DiBattiste, PM; Kowey, PR; Mudumbi, RV, 2011) | 0.9 |
"We compared on-demand dosing of dapoxetine alone and combined with mirodenafil in subjects with lifelong PE and without erectile dysfunction (ED)." | ( Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. Cho, JS; Cho, ST; Lee, SH; Lee, SK; Lee, WK; Lee, YS; Oh, CY; Yang, DY; Yoo, C, 2013) | 0.94 |
"Orally disintegrating tablet (ODT) is a user friendly and convenient dosage form." | ( Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet. Liew, KB; Peh, KK, 2021) | 0.62 |
" Therefore, a novel, accurate, specific and sensitive reversed-phase high performance liquid chromatographic method with fluorescence detection was developed and validated for their separation and quantitation in dosage form and human plasma using avanafil as an internal standard (IS)." | ( A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma. Ahmed Emad, el G; Amira, K; Maha, H; Mohamed, A, 2015) | 0.63 |
" The two models were applied on the dosage forms and statistically compared with the published HPLC method with no significant difference regarding accuracy and precision." | ( Linear Support Vector Regression and Partial Least-Squares for Determination of Dapoxetine Hydrochloride and Tadalafil in Binary Pharmaceutical Mixtures. Abdelhamid, NS; Anwar, BH; Magdy, MA; Naguib, IA, 2020) | 0.79 |
" The presented study is using previously analyzed pharmaceutical mixtures of Dapoxetine Hydrochloride (DAP) and Tadalafil (TAD) as a case study, whether in pure forms or in dosage form, where the study uses two datasets for analysis, the first aims to include COA and the second dataset avoids it, then a statistical comparison is conducted for training sets, test sets and dosage form datasets to see how far COA may interfere with analysis results." | ( Ultraviolet cutoff area and predictive ability of partial least squares regression method: A pharmaceutical case study. Abdallah, FF; Naguib, IA, 2020) | 0.79 |
" Based on the different effects of magnitude of the three dosing regimens, we recommend a stepwise approach, starting with 30 mg on demand, then 60 mg on demand and finally 60 mg dapoxetine daily." | ( Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis. Guo, Q; Li, YF; Zhang, YG; Zhao, GJ, 2019) | 1.02 |
" Eventually, the procedure was utilized in the dosage form assay and extended to include biological plasma analyses, with good percentage recuperation." | ( One-pot micellar augmented native fluorescence for facile fluorimetric assay of dapoxetine hydrochloride in biological plasma and tablets. Abu-Hassan, AA; Ali, R; Derayea, SM, 2020) | 0.79 |
"We suggested six simple, precise, and sensitive spectrophotometric methods based on mathematical filtration techniques and ratio spectra manipulations to resolve the spectra of DAP and SIL in their bulk and combined pharmaceutical dosage form and estimate the relevant individual concentrations." | ( Spectral analysis of severely overlapping spectra based on newly developed mathematical filtration techniques and ratio spectra manipulations: An application to the concurrent determination of dapoxetine and sildenafil in combined dosage form. Abd El-Hay, SS; Attala, K; Eissa, MS; El-Henawee, MM, 2021) | 0.81 |
"We determined the performance of the suggested methods for estimating DAP and SIL in their laboratory mixtures and their combined pharmaceutical dosage form." | ( Spectral analysis of severely overlapping spectra based on newly developed mathematical filtration techniques and ratio spectra manipulations: An application to the concurrent determination of dapoxetine and sildenafil in combined dosage form. Abd El-Hay, SS; Attala, K; Eissa, MS; El-Henawee, MM, 2021) | 0.81 |
Class | Description |
---|---|
naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 34.6713 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 21.5451 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 26.8325 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
Fumarate hydratase | Homo sapiens (human) | Potency | 34.3274 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
SMAD family member 3 | Homo sapiens (human) | Potency | 26.8325 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.8995 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 26.6032 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 29.8493 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
progesterone receptor | Homo sapiens (human) | Potency | 10.5909 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.9347 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
EWS/FLI fusion protein | Homo sapiens (human) | Potency | 24.2793 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253; AID1259255; AID1259256 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.1142 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 22.0180 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 33.0712 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 7.4978 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
G | Vesicular stomatitis virus | Potency | 18.4022 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 0.5977 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
polyprotein | Zika virus | Potency | 34.3274 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 10.5901 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 14.9589 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 33.4915 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 26.8325 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 22.6142 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 30.0450 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
Interferon beta | Homo sapiens (human) | Potency | 18.4022 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 18.4022 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 9.0131 | 0.0096 | 10.5250 | 35.4813 | AID1479145; AID1479148 |
Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 18.4022 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 18.4022 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (1.61) | 18.2507 |
2000's | 43 (23.12) | 29.6817 |
2010's | 98 (52.69) | 24.3611 |
2020's | 42 (22.58) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (82.82) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 46 (23.35%) | 5.53% |
Reviews | 42 (21.32%) | 6.00% |
Case Studies | 1 (0.51%) | 4.05% |
Observational | 5 (2.54%) | 0.25% |
Other | 103 (52.28%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |